Table 1. Prostate cancer (PC) cases, risk group distribution, management, and deaths after 18 yr for screening and control groups.
| Control (n=9949) | Screening (n=9950) | |||
|---|---|---|---|---|
|
| ||||
| All (n=9950) | Attendees (n=7647) | Non-attendees (n=2303) | ||
|
| ||||
| n (%) | n (%) | n (%) | n (%) | |
| PC cases | 962 (9.7) | 1396 (14) | 1272 (17) | 124 (5.4) |
|
| ||||
| PC stage, | ||||
| Low-riska | 254 (2.6) | 699 (7.0) | 682 (8.9) | 17 (0.74) |
| Intermediate-riskb | 359 (3.6) | 470 (4.7) | 438 (5.7) | 32 (1.4) |
| High-riskc | 170 (1.7) | 135 (1.4) | 103 (1.3) | 32 (1.4) |
| Advancedd | 118 (1.2) | 67 (0.67) | 34 (0.44) | 33 (1.4) |
| Missinge | 61 (0.61)e | 25 (0.25) | 15 (0.20) | 10 (0.43) |
|
| ||||
| Primary treatment | ||||
| Surveillancef | 321/962 (33) | 608/1396 (44) | 583/1272 (46) | 25/124 (20) |
| Radical prostatectomyg | 304/962 (32) | 529/1396 (38) | 499/1272 (39) | 30/124 (24) |
| Radiation | 95/962 (9.9) | 109/1396 (7.8) | 95/1272 (7.5) | 14/124 (11) |
| Endocrine treatment | 223/962 (23) | 137/1396 (9.8) | 84/1272 (6.6) | 53/124 (43) |
| Not treatede | 19/962 (2.0)e | 10/1396 (0.72) | 9/1272 (0.71) | 1/124 (0.81) |
| Missing | - | 3/1396 (0.21) | 2/1272 (0.16) | 1/124 (0.81) |
|
| ||||
| Metastatic prostate cancer | 179 (1.8) | 116 (1.2) | 69 (0.9) | 47 (2.0) |
|
| ||||
| Deaths from PC | 122 (1.23) | 79 (0.79) | 51 (0.67) | 28 (1.2) |
| Deaths from other causes | 2735 (27) | 2765 (28) | 1712 (22) | 1053 (46) |
a
T1, not N1 or M1, and Gleason score ≤6 and prostate-specific antigen (PSA) <10 ng/ml.
b
T1–2, not N1 or M1, with Gleason score ≤7, PSA <20 ng/ml or both; and not meeting the criteria for low risk.
c
T1–4, not N1 or M1, with Gleason score ≥8, PSA <100 ng/ml, or both; and not meeting the criteria for low or intermediate risk.
d
N1 or M1, or PSA ≥100 ng/ml.
e
Includes eight cases detected at autopsy.
f
Includes active surveillance and watchful waiting.
g
Includes nine cryosurgeries and 12 cystoprostatectomies.